Prova Education: Changing the Practice of Medicine

Changing the Practice of Medicine

Discover CME, tools, and guideline-focused education to
improve your knowledge - and patient outcomes.

Scorecards That Matter: Use MG-ADL, MG-MMT, QMG, QoL
Scorecards That Matter: Use MG-ADL, MG-MMT, QMG, QoL
MinuteCE®
Scorecards That Matter: Use MG-ADL, MG-MMT, QMG, QoL
1.00 program credit
- Christyn Edmundson, MD
1.00 program credit
Turning Flares Into Function: Flag Uncontrolled Disease
Turning Flares Into Function: Flag Uncontrolled Disease
MinuteCE®
Turning Flares Into Function: Flag Uncontrolled Disease
1.00 program credit
- Christyn Edmundson, MD
- Gil I. Wolfe MD, FAAN
1.00 program credit
Shared Goals, Shared Gains: Align With Patient Preferences
Shared Goals, Shared Gains: Align With Patient Preferences
MinuteCE®
Shared Goals, Shared Gains: Align With Patient Preferences
1.00 program credit
- Christyn Edmundson, MD
- Gil I. Wolfe MD, FAAN
1.00 program credit
FcRn: Same Class, Different Paths—Spot Agent Differentiators
FcRn: Same Class, Different Paths—Spot Agent Differentiators
MinuteCE®
FcRn: Same Class, Different Paths—Spot Agent Differentiators
1.00 program credit
- Christyn Edmundson, MD
- Gil I. Wolfe MD, FAAN
1.00 program credit
Target Locked in gMG: Why T2T Matters
Target Locked in gMG: Why T2T Matters
MinuteCE®
Target Locked in gMG: Why T2T Matters
1.00 program credit
- Christyn Edmundson, MD
- Gil I. Wolfe MD, FAAN
1.00 program credit
CME/CE In-Person & Virtual Event
Seeing the Invisible: Radiologic Precision to Enable Early Intervention in Bronchiectasis
April 13, 2026
Pittsburgh, Pennsylvania
1.00 credit Learn more
Seeing the Invisible: Radiologic Precision to Enable Early Intervention in Bronchiectasis
Seeing the Invisible: Radiologic Precision to Enable Early Intervention in Bronchiectasis
CME/CE Virtual Event
Seeing the Invisible: Radiologic Precision to Enable Early Intervention in Bronchiectasis
April 13, 2026
12:00 PM - 01:00 PM ET
1.00 credit Learn more
CME/CE In-Person Event
Seeing the Invisible: Radiologic Precision to Enable Early Intervention in Bronchiectasis
April 13, 2026
Pittsburgh, Pennsylvania
1.00 credit Learn more

CME/CE

MinuteCE®
Treat. Target. Transform: Applying Treat-to-Target Principles in the Management of Generalized Myasthenia Gravis (gMG)
1.00 credit 10 episodes
- Christyn Edmundson, MD
- Gil I. Wolfe MD, FAAN
1.00 credit 10 episodes
Minimal By Design: Define MSE Endpoints
Minimal By Design: Define MSE Endpoints
MinuteCE®
Minimal By Design: Define MSE Endpoints
1.00 program credit
- Christyn Edmundson, MD
- Gil I. Wolfe MD, FAAN
1.00 program credit
When to Begin FcRn: Initiation Criteria, Key Evidence
When to Begin FcRn: Initiation Criteria, Key Evidence
MinuteCE®
When to Begin FcRn: Initiation Criteria, Key Evidence
1.00 program credit
- Christyn Edmundson, MD
- Gil I. Wolfe MD, FAAN
1.00 program credit
The 2-Point Signal: Apply ≥2-Point Rule
The 2-Point Signal: Apply ≥2-Point Rule
MinuteCE®
The 2-Point Signal: Apply ≥2-Point Rule
1.00 program credit
- Christyn Edmundson, MD
- Gil I. Wolfe MD, FAAN
1.00 program credit
The 4-Hit Hypothesis: Foundations of IgAN Pathogenesis
The 4-Hit Hypothesis: Foundations of IgAN Pathogenesis
MinuteCE®
The 4-Hit Hypothesis: Foundations of IgAN Pathogenesis
1.00 program credit
- Richard Lafayette, MD, FACP
1.00 program credit
Emerging Therapies in IgAN: Who Could Benefit the Most?
Emerging Therapies in IgAN: Who Could Benefit the Most?
MinuteCE®
Emerging Therapies in IgAN: Who Could Benefit the Most?
1.00 program credit
- Richard Lafayette, MD, FACP
- Hong Zhang
1.00 program credit

Clinical Practice

Escalate With Intention: Stepwise, Target-Anchored Moves
Escalate With Intention: Stepwise, Target-Anchored Moves
MinuteCE®
Escalate With Intention: Stepwise, Target-Anchored Moves
1.00 program credit
- Christyn Edmundson, MD
- Gil I. Wolfe MD, FAAN
1.00 program credit
MinuteCE®
Inside the 4 Hits: Targeting APRIL to Change the Course of IgAN
1.00 credit 9 episodes
- Richard Lafayette, MD, FACP
- Dana Rizk, MD
- Hong Zhang
- Suzuki Yusuke, MD, PhD
1.00 credit 9 episodes
Mechanism-Based Targeting: Why APRIL Matters in IgAN
Mechanism-Based Targeting: Why APRIL Matters in IgAN
MinuteCE®
Mechanism-Based Targeting: Why APRIL Matters in IgAN
1.00 program credit
- Suzuki Yusuke, MD, PhD
- Dana Rizk, MD
1.00 program credit
APRIL Uncovered: An Upstream Driver in IgAN
APRIL Uncovered: An Upstream Driver in IgAN
MinuteCE®
APRIL Uncovered: An Upstream Driver in IgAN
1.00 program credit
- Dana Rizk, MD
- Hong Zhang
1.00 program credit
Translating Guidelines to Action in IgAN: Embracing a Simultaneous Dual-Concordant Approach
Translating Guidelines to Action in IgAN: Embracing a Simultaneous Dual-Concordant Approach
MinuteCE®
Translating Guidelines to Action in IgAN: Embracing a Simultaneous Dual-Concordant Approach
1.00 program credit
- Richard Lafayette, MD, FACP
- Suzuki Yusuke, MD, PhD
1.00 program credit
IgAN SOC: Strengths and Limits
IgAN SOC: Strengths and Limits
MinuteCE®
IgAN SOC: Strengths and Limits
1.00 program credit
- Dana Rizk, MD
- Suzuki Yusuke, MD, PhD
1.00 program credit

Programs

Beyond RAASi and Approved Therapies: The Unmet Needs in IgAN
Beyond RAASi and Approved Therapies: The Unmet Needs in IgAN
MinuteCE®
Beyond RAASi and Approved Therapies: The Unmet Needs in IgAN
1.00 program credit
- Hong Zhang
1.00 program credit
Emerging Evidence: IgAN Disease-Modifying Agents
Emerging Evidence: IgAN Disease-Modifying Agents
MinuteCE®
Emerging Evidence: IgAN Disease-Modifying Agents
1.00 program credit
- Richard Lafayette, MD, FACP
- Hong Zhang
1.00 program credit
Targeting Lower Proteinuria Levels: Shifting the Goalpost in IgAN
Targeting Lower Proteinuria Levels: Shifting the Goalpost in IgAN
MinuteCE®
Targeting Lower Proteinuria Levels: Shifting the Goalpost in IgAN
1.00 program credit
- Richard Lafayette, MD, FACP
- Suzuki Yusuke, MD, PhD
1.00 program credit
From Late-Line Rescue to Early-Line Option: The Potential for Bispecific Antibodies in Multiple Myeloma
From Late-Line Rescue to Early-Line Option: The Potential for Bispecific Antibodies in Multiple Myeloma
CME/CE
From Late-Line Rescue to Early-Line Option: The Potential for Bispecific Antibodies in Multiple Myeloma
0.25 credits
- María-Victoria Mateos, MD, PhD
- Luciano Costa, M.D., Ph.D.
0.25 credits
Advancing Care in HNSCC: Evolving Strategies Across the Disease Continuum
Advancing Care in HNSCC: Evolving Strategies Across the Disease Continuum
CME/CE
Advancing Care in HNSCC: Evolving Strategies Across the Disease Continuum
0.50 credits
- Kevin J Harrington, PhD, FRCP, FRCR, FRSB
- Cristina Rodriguez, MD
0.50 credits
NSCLC Data Review: Efficacy and Safety Data for ON-State RAS Inhibitors
NSCLC Data Review: Efficacy and Safety Data for ON-State RAS Inhibitors
MinuteCE®
NSCLC Data Review: Efficacy and Safety Data for ON-State RAS Inhibitors
0.75 program credits
- Kathryn Arbour
0.75 program credits

Changing the Practice of Medicine

Popular

CME/CE

Clinical Practice

Programs

Title

Share on ReachMD